Portal de investigación
Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Vey N.
- Salamero O.
- Bajel A.
- Daver N.
- Prebet T.
- Legrand O.
- Récher C.
- Maillard A.
- Hemon A.
- de Burgat V.
- Ervin-Haynes A.
- Broniscer A.
- Wei A.H.
Grupos
Abstract
Preclinical data support myeloid cell leukemia 1 (MCL1) inhibition in the treatment of acute myeloid leukemia (AML). Patients with relapsed/refractory myelodysplastic syndrome (n = 1) or AML (n = 32) or older patients with untreated AML ineligible to receive intensive chemotherapy (n = 5) were treated in this phase 1 study of S64315, an MCL1 inhibitor (NCT02979366). Seven dose levels (50, 100, 200, 250, 300, 400, and 500 mg) were tested. The most common toxicities were nausea and vomiting, diarrhea, and increased transaminases and troponin levels. Seven patients experienced dose-limiting toxicities (DLTs), including increased cardiac biomarkers (n = 3), grade 3 increased transaminases with hyperbilirubinemia (n = 2), and decreased cardiac ejection (n = 1). Three DLTs occurred at the 500-mg dose, which was intolerable; a maximum tolerated dose was not determined since fewer than six patients were treated at doses between 100 and 400 mg. Exposure to S64315 increased in a dose-dependent manner between 50 and 500 mg. There were no objective responses to therapy. © 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Datos de la publicación
- ISSN/ISSNe:
- 1042-8194, 1029-2403
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 42503467
- Enlace a otro recurso:
- www.scopus.com
- Factor de Impacto:
- 0,741 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
LEUKEMIA & LYMPHOMA TAYLOR & FRANCIS LTD
Citas Recibidas en Web of Science: 1
Documentos
- No hay documentos
Filiaciones
Keywords
- cell cycle and apoptosis changes; Myeloid leukemias and dysplasia; pharmacotherapeutics
Cita
Vey N,Salamero O,Bajel A,MONTESINOS P,Daver N,Prebet T,Legrand O,Récher C,Maillard A,Hemon A,de Burgat V,Ervin A,Broniscer A,Wei AH. Phase 1 clinical trial of S64315, an intravenous MCL1 inhibitor, in patients with myeloid malignancies. Leuk. Lymphoma. 2026. IF:2,100. (3).